Trials / Completed
CompletedNCT00116662
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (planned)
- Sponsor
- Graceway Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 3 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks. A second purpose is to evaluate the safety of the drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Resiquimod |
Timeline
- Start date
- 2005-03-01
- First posted
- 2005-07-01
- Last updated
- 2007-02-19
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00116662. Inclusion in this directory is not an endorsement.